Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
about
Advances in Diagnosis and Treatments for Immune ThrombocytopeniaCommon variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with RituximabPathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.Current treatment options for primary immune thrombocytopenia.Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice.High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia.Cellular immune dysfunction in immune thrombocytopenia (ITP).Contemporary treatment of immune thrombocytopenia.Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration.A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP.Common variable immunodeficiency, immune thrombocytopenia, rituximab and splenectomy: important considerations.Interferon-alpha triggers B cell effector 1 (Be1) commitmentThe emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses.Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.B cell depletion in treating primary biliary cirrhosis: pros and consIL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody productionChallenges in the diagnosis and management of autoimmune hepatitis.The impact of biologic response modifiers on hepatitis B virus infection.Antibodies in the treatment of aplastic anemia.Biologics in oral medicine: principles of use and practical considerations.Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children.B cells and progressive multifocal leukoencephalopathy: search for the missing linkResponse of patients with refractory myasthenia gravis to rituximab: a retrospective study.Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.Autoimmune hemolytic anemia and nodular lymphocyte-predominant hodgkin lymphoma: a rare association.Involvement of (IgG and IgM)-secreting B lymphocytes in severity of autoimmune hepatitis type 1.A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.High frequency of circulating follicular helper T cells is correlated with B cell subtypes in patients with ankylosing spondylitis.
P2860
Q26738630-46C7EE5E-BDF2-4C78-92BA-69E79534C99DQ31150752-AC77B14D-578F-450E-AEAE-9BB12C6EA5BEQ33392868-B63501C9-3500-4BCC-BDA7-C6BD538A6A66Q33394149-6F80465D-79A7-4064-BDCC-EDF730552CA3Q33402209-167778F3-3440-4A75-925D-4F07D6E8CB8AQ33404032-539EB2D2-FFC0-43B1-A2A0-E864F6887DD4Q33406310-E08D8219-2D59-4CA3-BE26-AA7A9F967960Q33409710-C9314BEE-FCE8-409D-9E5E-23A149D0FEE2Q33410653-D8EFB2ED-1CC7-4E4F-AC9E-D76250564ED0Q33414722-D1138540-DB4F-4AE3-AB06-C56517A046B3Q33419712-FA1FC0B6-8C9E-4444-B29C-7EE9FDFF3BC3Q33432871-3C7941A4-97A4-4230-9F9A-64692267CD30Q33895026-188DF049-D577-4461-8C66-9427F03B5B60Q34373452-F5546AFF-9AE7-41EA-BEE5-6521B07D2B2AQ35059951-8A721371-8843-424D-A9BA-2C66B9668A58Q35230227-4787760C-2CEB-4282-A797-36A5F23A76DEQ35286950-642130B9-E2ED-4D2D-9548-72FB406602FFQ36166941-E609E8DA-4DED-4FBA-A608-CA1438E454C3Q36376751-5426266D-472E-456A-A3BF-A896D7132495Q37640582-3966C4B6-B7DE-4BDE-90B4-77EED8A177FCQ37832503-352259A7-594B-4318-ACD5-BD84F2E6363CQ37981576-0F0B4269-B7ED-4FA1-8399-64A72BA4240EQ37993932-C5FDB872-0958-4AAE-9AE1-34BAB7D38C7EQ38193672-852B7315-E2D6-4C0C-973A-4D3BD30CDAB8Q38515349-ECF8F1DF-AE7C-4579-B64D-D150EF6BE331Q38633453-AC8F956E-DE63-41CE-8B4B-D6A49485B70CQ40097140-68B2FC49-2604-4965-9F80-C80752E89478Q40246473-94B5BD63-7A86-41D1-BC5A-A45443A1C307Q43486269-0126B571-E924-4479-B510-91D26DA8E27BQ47690234-92AFCDCB-C93B-4701-A585-54432BB40106Q55054505-85FC2D61-7EA3-470C-B3C6-6832A7ED8B9A
P2860
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@ast
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@en
type
label
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@ast
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@en
prefLabel
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@ast
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@en
P1476
Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
@en
P2093
Roberto Stasi
P304
P356
10.1053/J.SEMINHEMATOL.2010.01.010
P577
2010-04-01T00:00:00Z